OVerview
Lumeda is a clinical-stage medtech company focused on improving outcomes for patients diagnosed with lung cancer based on our breakthrough DigiLum™ Photodynamic Therapy (PDT) platform. This system is designed to efficiently activate a photosensitizer drug in the thoracic cavity and deliver PDT to extend patient survival and improve their quality of life.
TEAM
Lumeda was formed late 2019 by an experienced management team with a track record of creating successful new ventures. Working alongside a leading national cancer center, we are a multidisciplinary team committed to introducing new light-activated treatment modalities for cancer. We strive for technical excellence and work to the highest ethical standards.
INDICATIONS
Lumeda is targeting thoracic applications for DigiLum™ that apply PDT intraoperatively during standard of care procedures. Our lead indication is for use of DigiLum™ to extend survival of patients with late-stage lung cancer by priming the host immune system to stimulate anti-tumor immunity for an improved response to standard of care immunotherapy.